7-methyl-5-(4-(morpholine-4-carbonyl)phenyl)imidazo[1,5-a]pyrazin-8(7H)-one

ID: ALA4551010

PubChem CID: 155555073

Max Phase: Preclinical

Molecular Formula: C18H18N4O3

Molecular Weight: 338.37

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cn1cc(-c2ccc(C(=O)N3CCOCC3)cc2)n2cncc2c1=O

Standard InChI:  InChI=1S/C18H18N4O3/c1-20-11-16(22-12-19-10-15(22)18(20)24)13-2-4-14(5-3-13)17(23)21-6-8-25-9-7-21/h2-5,10-12H,6-9H2,1H3

Standard InChI Key:  QXZBKUFEQPBGMJ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   12.8109   -2.4062    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.8109   -3.2234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5162   -3.6278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5162   -1.9935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5158   -4.4442    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8064   -4.8522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8061   -5.6686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5143   -6.0780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2244   -5.6650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2212   -4.8500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2215   -2.4062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2214   -3.2244    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.9996   -3.4773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4806   -2.8153    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.9997   -2.1534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5162   -1.1763    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.1020   -1.9997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5154   -6.8952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8082   -7.3048    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.2237   -7.3029    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.2214   -8.1190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9256   -8.5266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.6352   -8.1206    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.6361   -7.3024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9274   -6.8903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  4  1  0
  2  3  2  0
  3 12  1  0
 11  4  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10  5  1  0
  3  5  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 11  2  0
  4 16  2  0
  1 17  1  0
  8 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  1  0
 20 25  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4551010

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 338.37

Molecular Weight (Monoisotopic): 338.1379

AlogP: 1.17

#Rotatable Bonds: 2

Polar Surface Area: 68.84

Molecular Species: NEUTRAL

HBA: 6

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 1.91

CX LogP: -0.14

CX LogD: -0.14

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.70

Np Likeness Score: -1.26

References

1. Zheng P, Zhang J, Ma H, Yuan X, Chen P, Zhou J, Zhang H..  (2019)  Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.,  27  (7): [PMID:30824168] [10.1016/j.bmc.2019.02.045]

Source

Source(1):

• Scientific Literature